Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Genaera Shifts Focus From AMD To Obesity

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company switches gears in the wake of Genentech’s Lucentis launch.

You may also be interested in...



Genaera Discontinues Phase II Studies Of Lomucin And Squalamine

Termination of the studies reflects Genaera’s decision to focus on core assets trodusquemine for obesity and anti-IL-9 program for asthma.

Genaera Discontinues Phase II Studies Of Lomucin And Squalamine

Termination of the studies reflects Genaera’s decision to focus on core assets trodusquemine for obesity and anti-IL-9 program for asthma.

Acomplia User Fee Date For Weight Loss Is April 26

Sanofi-Aventis has not determined a timetable for responding to FDA’s “not approvable” letter for a smoking cessation claim.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS065135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By